Medicilon's cardiac safety evaluation services-patch clamp system

Cardiac safety evaluation is an important factor that must be investigated before various new drugs enter clinical trials, and it is also one of the most important and difficult links in the early clinical research of innovative drugs. The QT interval of the heart refers to the period from the beginning of the QRS complex to the end of the T wave, including the process of ventricular depolarization and repolarization. The QT interval is considered to be one of the key indicators for the safety evaluation of new drugs. In cardiomyocytes, the potassium channel encoded by hERG (human Ether-a-go-go Related Gene) mediates a delayed rectifier potassium current (IKr), and IKr inhibition is an important mechanism by which drugs lead to prolongation of the QT interval. hERG can be inhibited by compounds with diversified structures. The loss of its function or drug inhibition will affect the repolarization process of cardiac action potentials and cause the QT interval to prolong. At the same time, it can induce torsade de pointes ventricular tachycardia and cause arrhythmia.

With the continuous deepening of research, the safety evaluation technology of hERG inhibition has become more mature. At present, there are many mature evaluation methods on the market, such as Automated Patch-Clamp technology (Automated Patch-Clamp), traditional patch-clamp technology ( ConventionalPatch-Clamp) and FluxORTM Thallium Assay.

The basic principle of patch clamp (Patch Clamp) is to use a glass electrode with a tip diameter of 0.5-1um to be attached to the surface of the cell membrane. The electrode tip and the cell membrane are tightly sealed by suction through negative pressure, so that the cell membrane is connected to the center of the electrode tip. The patch is electrically insulated from its surroundings, and the membrane potential (clamp) is fixed on this basis, and then the current of one or several ion channels on the cell membrane with an area of only a few square microns under the electrode tip is recorded. Thus, the electrophysiological technology is improved to the molecular level of recording and studying individual proteins.

Patch clamp technology has been widely used in myocardial ion channel research related to drug action, the study of the relationship between single cell morphology and function, drug action mechanism, cardiovascular pharmacological research, innovative drug research and high-throughput screening.

Medicilon introduced the HEKA Patch Clamp System, which is an integrated amplifier and digital-to-analog converter. It can be combined with manual operation through software to achieve a more accurate degree than full automatic, which will greatly enhance Medicilon Western in vitro drug safety evaluation service.

The Medicilon Drug Safety Evaluation Center is composed of a group of experienced professional scientific research teams. It has established a drug safety evaluation system that meets international standards. The experimental research follows the guidelines of ICH, CFDA, FDA and OECD, and can provide high-quality data and fast With the drug preclinical safety evaluation service in the research cycle, Medicilon helps customers shorten the experimental time and reduce the cost of new drug research and development through cost-control and efficient services. Since 2012, Medicilon has successfully helped nearly 50 customers submit application materials that meet the requirements of new drug registration to CFDA, FDA and TGA, and has accepted and passed more than 100 verifications.

hERG test-preclinical cardiac safety evaluation

hERG Assay – Drug Preclinical Cardiac Safety Assessment

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客